Literature DB >> 16502427

The von Hippel-Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma.

Mary-Alice Abbott1, Katherine L Nathanson, Simon Nightingale, Eamonn R Maher, Robert M Greenstein.   

Abstract

Von Hippel-Lindau (VHL) disease is a heritable tumor susceptibility syndrome caused by germline mutations in the VHL gene. The types of tumor that can occur in affected individuals include retinal and central nervous system hemangioblastoma, renal cell carcinoma, pheochromocytoma, and others. The pattern of tumor types that develops in a VHL-affected family defines the clinical subtype (1, 2A, 2B, 2C). Generally, it is difficult to accurately predict an individual's clinical phenotype based on their VHL mutation. However, in a few specific VHL mutations, a strong genotype-phenotype correlation has been established. We report here on the clinical findings in individuals from three unrelated families with a V84L VHL germline mutation, and present follow-up information regarding the only other reported family with this missense mutation. In each of these four families, the major clinical manifestation of VHL disease is multiple early-onset pheochromocytomas (VHL type 2C). This series of eight patients strengthens the correlation between the V84L mutation and the VHL type 2C phenotype, and improves our ability to provide prognostic and management recommendations for similarly affected individuals. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16502427     DOI: 10.1002/ajmg.a.31116

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  9 in total

1.  Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.

Authors:  R Rajasekaran; C Sudandiradoss; C George Priya Doss; Anshuman Singh; Rao Sethumadhavan
Journal:  Mamm Genome       Date:  2008-10-03       Impact factor: 2.957

2.  Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.

Authors:  A D Sorrell; S Lee; C Stolle; J Ellenhorn; A Grix; W G Kaelin; J N Weitzel
Journal:  Clin Genet       Date:  2011-06       Impact factor: 4.438

3.  VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.

Authors:  Katja Knauth; Edward Cartwright; Stefan Freund; Mark Bycroft; Alexander Buchberger
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

Review 4.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

5.  P.Arg82Leu von Hippel-Lindau (VHL) gene mutation among three members of a family with familial bilateral pheochromocytoma in India: molecular analysis and in silico characterization.

Authors:  Anulekha Mary John; George Priya Doss C; Andrew Ebenazer; Mandalam Subramaniam Seshadri; Aravindan Nair; Simon Rajaratnam; Rekha Pai
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 6.  Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack.

Authors:  João Castro-Teles; Bernardo Sousa-Pinto; Sandra Rebelo; Duarte Pignatelli
Journal:  Endocr Connect       Date:  2021-10-27       Impact factor: 3.335

7.  Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata.

Authors:  Michael Ohh; Cassandra C Taber; Fraser G Ferens; Daniel Tarade
Journal:  Elife       Date:  2022-08-30       Impact factor: 8.713

8.  Molecular Characterization of a Novel Germline VHL Mutation by Extensive In Silico Analysis in an Indian Family with Von Hippel-Lindau Disease.

Authors:  Gautham Arunachal; Divya Pachat; C George Priya Doss; Sumita Danda; Rekha Pai; Andrew Ebenazer
Journal:  Genet Res Int       Date:  2016-03-16

9.  New Insights Into Pheochromocytoma Surveillance of Young Patients With VHL Missense Mutations.

Authors:  Gustavo F C Fagundes; Janaina Petenuci; Delmar M Lourenco; Ericka B Trarbach; Maria Adelaide A Pereira; Joya Emilie Correa D'Eur; Ana O Hoff; Antonio M Lerario; Maria Claudia N Zerbini; Sheila Siqueira; Fernando Yamauchi; Victor Srougi; Fabio Y Tanno; Jose Luis Chambo; Ana Claudia Latronico; Berenice B Mendonca; Maria Candida B V Fragoso; Madson Q Almeida
Journal:  J Endocr Soc       Date:  2019-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.